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initial diagnostic test were identiﬁed from a multicenter database
using complete facility, physician and pharmacy data from two
large health care plans from 2003–05. 1-year downstream CAD-
related episodes of care were examined for patients after initial
MDCT or MPI. Costs were further sub-classiﬁed by utilization of
high-cost resources, including cardiac catheterization, percutane-
ous transluminal coronary angioplasty (PTCA), and coronary
artery bypass surgery (CABG). RESULTS: A total of 18,489
patients underwent either MDCT (n = 638) or MPS (n = 17,851)
testing during the study period. While costs per CAD-related
episodes were similar between MDCT and MPS groups ($5,878
vs. $6,079, p = 0.20), patients undergoing MDCT had fewer
total numbers of CAD-related episodes of care (4.246 vs. 5.065,
p < .0001). High-cost CAD test utilization was also lower for
MDCT patients compared to MPI patients for cardiac catheter-
ization (15.673 vs. 29.132, p < 0.0001), PTCA (0.940 vs. 2.341,
p = 0.020), and CABG (2.351 vs. 5.274, p = 0.001). After adjust-
ment for age, gender, baseline cardiovascular risk, and baseline
health status, one-year total CAD-related episodes of care costs
for MDCT were 16.4% lower than MPS, by an average of $800
(95% CI, $39-$1394) per patient. CONCLUSION: Patients
without known CAD who undergo MDCT as an initial diagnos-
tic test, compared to MPI, incurred fewer CAD-related episodes
of care and underwent fewer incident high-cost tests. These data
suggest that MDCT may be a potential cost-saving alternative to
MPS for initial evaluation of patients with suspected CAD.
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OBJECTIVES: The general objective of this study was to develop
an explicit pharmacoeconomic threshold for purposes of phar-
maceutical decision making in South Africa (SA). METHODS:
For the determination of a pharmacoeconomic threshold for
pharmaceutical decision-making in SA, the method of the WHO,
namely the “three-times-GDP per capita” approach, was used.
To determine the GDP per capita for each health care sector, i.e.
private and public, in SA it was needed to determine the income
and number of people in each sector. The GDP for the public
sector was calculated by dividing the income generated in
the public sector by the total income generated in SA and
then multiplying it by the total GDP (Total GDP according to
Statistics South Africa in 2006 = R1,726,688,000,000 (US$
246,700,000,000)). The same formula will be used to determine
the GDP for the private sector. To determine the total income in
each sector, data from the All Media Products Survey (AMPS)
was used. The average income was calculated in 2006 prices.
The number of people in the public sector is determined by using
the 2003 ASSA (Actuarial Society of South Africa) model, and
subtracting the number of medical scheme beneﬁciaries accord-
ing to the 2005–06 Council for Medical Schemes report.
RESULTS: The GDP for the public sector was estimated at
R990,831,925,794 and the GDP for the private sector at
R735,856,074,206. The total SA population was estimated
at 47,866,985, with the number of people in the private sector at
6,835,621 and 41,031,364 people utilising the public health care
sector. The GDP/capita in the private and public sector was
estimated as R107,650 and R24,148 respectively. CONCLU-
SION: The threshold for the private health care sector is
R322,950, for the public sector it is R72,444 and for SA the
threshold for pharmaceutical decision making is R108,218.
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OBJECTIVES: We aimed to evaluate the clinical outcome of
BMS and DES placement in coronary artery disease patients and
estimate the cost of BMS and DES placement in a Chinese popu-
lation. METHODS: It was a retrospective cross-sectional study.
We included all patients who underwent PCI with stent place-
ment of either DES or BMS in a tertiary public hospital in Hong
Kong over 4-month period. Patients were followed up for the
occurrence of MACE within 12 months of the index stent place-
ment. MACE was deﬁned as cardiac death, non-fatal myocardial
infarction and target lesion revascularization. Direct medical
costs were estimated based on the procedural cost, hospitaliza-
tion, medications, cardiac follow-up and repeated interventions
taken. RESULTS: This interim analysis included 184 patients.
Twelve-month MACE rate was 12.2% in BMS versus 3.4% in
DES (p = 0.042). Rate of cardiac death was 3.7% in BMS versus
0% in DES group (p = 0.110). The mean 12-month cost
per patient after index PCI was USD 8827.6  5634.0
(median = 7268.2) in DES and USD 7222.4  4538.1 (median =
6170.5) in BMS. On average, DES costs USD 1605.1 more than
BMS per patient. CONCLUSION: Routine usage of DES is more
costly than BMS that may discourage the use of DES in our
public hospital setting. This may be explained by the less than
expected difference in 12-month MACE between DES and BMS
in our population and the lower hospitalization costs in Hong
Kong. Further cost-effectiveness analysis will be conducted to
evaluate the differences between DES and BMS.
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OBJECTIVES: Dyslipidemia is a risk factor for coronary heart
disease (CHD), which remains a leading cause of U.S. mortality,
irrespective of sex, race/ethnicity, or age. Because the beneﬁts of
antilipidemics extend across patient characteristics, antilipidemic
initiation rates should not widely vary by patient demographics.
We conducted a large-scale retrospective claims analysis to
conﬁrm this assumption among newly-diagnosed adult dyslipi-
demic patients. METHODS: Nine-year (1997–2006) retrospec-
tive claims analysis of Florida Medicaid adults (18 years) who
had 1 year of data before and 3 years of data following their
ﬁrst dyslipidemia (ICD-9 272.X) diagnosis. Charlson Index
classiﬁed disease burden. Logistic regression examined odds
ratios. RESULTS: Among 231,110 dyslipidemic patients, 19,128
meeting eligibility criteria received antilipidemics during the
index period; 18,346 did not. Women were 8% less likely to
receive antilipidemics (OR 0.92, 95% CI 0.88–0.96, p = 0.0005)
than men. Treatment initiation rates among Hispanics did not
signiﬁcantly differ from Whites. Blacks were 23% less likely (OR
0.77, 95% CI 0.73–0.81, p < 0.0001), and Other Ethnicities/
Races 17% more likely (OR 1.17, 95% CI 1.11–1.24,
p < 0.0001) to receive antilipidemics during the follow-up period
than Whites. Patients aged 50–64 years were 17% more likely
(OR 1.17, 95% CI 1.10–1.25, p < 0.0001), and those aged
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